- Home
- KALV vs DPG Comparison
KALV vs DPG Comparison
Compare KALV & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KALV | DPG |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.7M | 535.3M |
| IPO Year | 2014 | 2011 |
Fundamental Metrics
Financial Performance| Metric | KALV | DPG |
|---|---|---|
| Price | $18.49 | $14.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.60 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 83.0K |
| Earning Date | 03-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000,000.00 | N/A |
| Revenue This Year | $122.34 | N/A |
| Revenue Next Year | $99.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $10.45 |
| 52 Week High | $19.95 | $14.96 |
Technical Indicators
Market Signals| Indicator | KALV | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 51.64 |
| Support Level | $14.66 | $14.04 |
| Resistance Level | $18.85 | $14.81 |
| Average True Range (ATR) | 1.22 | 0.25 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 67.90 | 44.23 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.